Literature DB >> 18422782

A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation.

Matthew J Hourigan, James Doecke, Peter N Mollee, Devinder S Gill, Debra Norris, David W Johnson, Maher K Gandhi.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 18422782     DOI: 10.1111/j.1365-2141.2008.07149.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

Review 1.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

2.  Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil.

Authors:  Brett J Loechelt; David Boulware; Michael Green; Lindsey R Baden; Peter Gottlieb; Heidi Krause-Steinrauf; Adriana Weinberg
Journal:  Clin Infect Dis       Date:  2012-10-05       Impact factor: 9.079

3.  Monomorphic Post-transplant Lymphoproliferative Disorder After Kidney Transplantation and Hematopoietic Stem Cell Transplantation: Clinicopathological Characteristics, Treatments and Prognostic Factors.

Authors:  Li Fu; Jianlan Xie; Jun Lin; Jingshi Wang; Na Wei; Dayong Huang; Tingting Wang; Jing Shen; Xiaoge Zhou; Zhao Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2017-03-03       Impact factor: 0.900

Review 4.  Viral infection in renal transplant recipients.

Authors:  Jovana Cukuranovic; Sladjana Ugrenovic; Ivan Jovanovic; Milan Visnjic; Vladisav Stefanovic
Journal:  ScientificWorldJournal       Date:  2012-05-02

5.  Prognostic superiority of International Prognostic Index over [18F]FDG PET/CT volumetric parameters in post-transplant lymphoproliferative disorder.

Authors:  F Montes de Jesus; D Dierickx; V Vergote; W Noordzij; R A J O Dierckx; C M Deroose; A W J M Glaudemans; O Gheysens; T C Kwee
Journal:  EJNMMI Res       Date:  2021-03-18       Impact factor: 3.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.